FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesNavigating Regulatory and QA Challenges in Clinical Supply Management
Topic: Regulatory
Executive Summary
Members
Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
GCSG sponsored study on INVESTIGATIVE SITE Receptivity to Direct-to-Patient Shipment in Clinical Trials
Topic: Direct-to-Patient
White Paper
Members
